Tunisia
Tuberculosis profile
Population  2012 11 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.32 (0.17–0.5) 2.9 (1.6–4.6)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.01)
Prevalence  (includes HIV+TB) 4.5 (1.7–8.5) 41 (16–78)
Incidence  (includes HIV+TB) 3.4 (3–3.8) 31 (27–35)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.06 (0.05–0.07)
Case detection, all forms (%) 96 (84–110)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 059 (33) Relapse 45 (70)
Smear-negative 179 (6) Treatment after failure 1 (2)
Smear-unknown / not done 103 (3) Treatment after default 7 (11)
Extrapulmonary 1 853 (58) Other 11 (17)
Other 0 (0)      
Total new 3 194   Total retreatment 64  
           
Other (history unknown) 0        
Total new and relapse 3 239   Total cases notified 3 258  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.2 1.7 0.6
Age < 15 17 6 181
Laboratories 2012
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 5.1
Drug susceptibility testing (per 5 million population) 2.3
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 87   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 73  
Retreatment 79  
TB/HIV 2012 Number (%)
TB patients with known HIV status 593 (18)
HIV-positive TB patients 14 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 14 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 14 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 54  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.82 (0–1.7) 12 (4.5–19)
MDR-TB cases among notified pulmonary
TB cases
11 (0–23) 8 (3–12)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 3 (<1%) 12 (19%) 15
Laboratory-confirmed MDR-TB cases 3 12 15
Patients started on MDR-TB treatment     15
Financing TB control 2013
National TB programme budget (US$ millions) 1.3
% Funded domestically 45%
% Funded internationally 55%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data